Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter ended June 30, 2026
Currency: Indian Rupees (INR) with U.S. Dollar (USD) convenience translation (Rate: $1.00 = Rs. 94.66)
DRL is a leading India-based pharmaceutical company with principal markets in India, Russia, the United States, and Germany. The company operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others (including Aurigene Oncology and Proprietary Products).
Key Financial Metrics
| Metric (in millions) | Q1 FY2027 (Ended June 30, 2026) | Q1 FY2026 (Ended June 30, 2025) |
|---|---|---|
| Revenues | Rs. 80,705 (U.S.$ 853) | Rs. 85,452 |
| Gross Profit | Rs. 37,540 (46.5% margin) | Rs. 48,627 (56.9% margin) |
| Operating Profit | Rs. 3,784 (4.7% margin) | Rs. 17,475 (20.5% margin) |
| Profit Before Tax | Rs. 5,526 | Rs. 19,047 |
| Net Profit (Period) | Rs. 4,348 (5.4% margin) | Rs. 14,096 (16.5% margin) |
| Net Profit (Attributable to Parent) | Rs. 4,435 | Rs. 14,178 |
| EPS (Basic) | Rs. 5.32 | Rs. 17.04 |
| Cash & Equivalents (End of Period) | Rs. 11,204 | Rs. 15,368 |
| Working Capital | Rs. 141,990 | Rs. 134,409 |
| Total Debt (Short + Long Term) | Rs. 71,952 | Rs. 77,338 |
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenues decreased by 6% (Rs. 4,747 million) primarily due to a 35% drop in North American revenues (Rs. 22,048 million vs. Rs. 34,123 million). This was driven by price erosion and volume declines in existing products. The decline was partially offset by growth in Emerging Markets (+31%), India (+17%), and Europe (+13%).
- Margin Compression: Gross profit margin fell from 56.9% to 46.5%. This was driven by price erosion, unfavorable product mix shifts, and a specific provision of Rs. 2,397 million related to out-of-specification Semaglutide inventory.
- Profitability Drop: Net profit attributable to equity holders plummeted by 69% (Rs. 4,435 million vs. Rs. 14,178 million). Operating profit dropped 78% due to the revenue decline and increased SG&A expenses (up 12% due to personnel costs and freight).
- Effective Tax Rate: The effective tax rate decreased to 21.32% from 25.99%, aided by the reversal of previously recognized tax provisions and a shift in profit mix toward lower-tax jurisdictions.
- Cash Flow: Operating cash flow turned negative at Rs. (927) million compared to an inflow of Rs. 14,629 million in the prior year, largely due to working capital requirements and lower profitability.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Semaglutide Provision: A provision of Rs. 2,397 million was recorded for inventory and associated costs due to batches found out of specification.
- Finance Income: Net finance income increased to Rs. 1,734 million (from Rs. 1,570 million) driven by a net foreign exchange gain of Rs. 909 million and fair value gains on investments (Rs. 1,081 million).
- Regulatory & Legal:
- Ranitidine Litigation: The company continues to defend itself in MDL 2924 and state court actions. It recently entered into confidential master settlement agreements to resolve pending cases in California and Illinois. No provision has been made as the company believes claims are without merit.
- FDA Inspections: Seven observations were noted in a June 2026 inspection of the Biologics facility in Hyderabad and a September 2025 inspection of the API facility in Mirfield, UK. The company has responded to all observations.
- Geopolitical Risks: The company monitors impacts from conflicts in Russia/Ukraine and the Middle East. While revenue from Russia increased 28%, management expects to fully recover asset carrying amounts despite ongoing instability.
- Outlook: The company filed five new ANDAs and one NDA in the quarter. It maintains 79 filings pending with the U.S. FDA. Management expects to meet working capital requirements through internal funds and existing credit lines (Rs. 56,471 million available).
Investor Verification Checklist
- Semaglutide Impact: Verify the extent of the Rs. 2,397 million inventory provision and its impact on future margins for this high-profile product.
- North America Recovery: Assess the sustainability of the 35% revenue decline in the U.S. market and the pipeline of new product launches to offset price erosion.
- Ranitidine Settlements: Monitor the finalization of the confidential settlement agreements in California and Illinois to determine if any material costs were underestimated.
- Working Capital Trends: Review the increase in Days Sales Outstanding (DSO) from 93 to 108 days and the negative operating cash flow to ensure liquidity remains sufficient.
- Regulatory Compliance: Track the resolution of FDA observations at the Hyderabad and Mirfield facilities to ensure no export bans or restrictions are imposed.